Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New method allows the discovery of specific inhibitors of lactate transporter

Scientists from the Giulio Superti-Furga Lab at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have developed a new method that allows the discovery of specific inhibitors of a lactate transporter associated with cancer and other disease areas.

28 Jul 2023

Embracing nature's medicine: exploring medicinal plants for diabetes treatment

Researchers described 20 medicinal plants, their bioactive phytochemical components, therapeutic potential, modes of action, and prospects and ability to combat diabetes mellitus.

27 Jul 2023

MD Anderson and Nexo Therapeutics partner to advance new cancer therapies against previously undruggable targets

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns the innovative technology and capabilities of each organization at the earliest stages of drug discovery and development to rapidly advance impactful new cancer therapies against previously undruggable targets.

26 Jul 2023

Meclofenamate shows promise in treating abnormal respiratory mucus

Our respiratory system is lined with a thin fluid layer called mucus on the inside. The mucus protects us from inhaling harmful and unwanted airborne agents from germs to pollutants; it achieves this feat due to its unique gel-like texture imparted by proteins called mucins.

25 Jul 2023

Advancing new antibiotics through the later stages of clinical testing

A report by University of Queensland researchers has warned a global crisis of antibiotic resistance is inevitable, despite promising developments in new antibiotics.

25 Jul 2023

AXT and CELLINK Form a Formidable Australian Bioprinting Partnership

3D bioprinting is experiencing rapid growth as the technology continues to evolve. This is certainly the case in Australia and AXT, who are already well entrenched in the field are pleased to announce that they are strengthening their position by partnering with CELLINK.

From AXT Pty Ltd 25 Jul 2023

New INTREPID Alliance aims to speed up development of antivirals for future pandemics

Seven innovative pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.

24 Jul 2023

Scripps Research scientists develop AI tool to track the detailed evolution of viral pandemics

Scripps Research scientists have developed a machine-learning system-;a type of artificial intelligence (AI) application-;that can track the detailed evolution of epidemic viruses and predict the emergence of viral variants with important new properties.

21 Jul 2023

Realizing the Potential of Vendor Engagement

In this interview conducted in anticipation of ELRIG's Drug Discovery 2023 Conference, we spoke to Nick Clare, Vendor Strategy Work Group Lead for ELRIG, about what vendors can gain from attending ELRIG events, such as Drug Discovery 2023.

21 Jul 2023

Researchers develop novel system to identify new therapeutics for familial hypercholesterolemia

The Mona Lisa, painted by the Italian artist Leonardo da Vinci, is one of the most recognizable paintings in the world. But many people would be surprised to learn that this painting offers the first evidence of a disease called familial hypercholesterolemia (FH).

20 Jul 2023

High body temperature may boost gut microbiota to fight viral infections

Researchers from The University of Tokyo unravel the connection between high body temperature and increased viral resistance.

20 Jul 2023

Arrayjet announces collaboration with Chemspace to augment its small molecule microarray services for drug discovery

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that it has partnered with Chemspace, the largest online catalogue of small molecules and biologics, to augment and streamline the Company’s small molecule microarray (SMM) service offering.

From Arrayjet Ltd 19 Jul 2023

Understanding the mechanisms behind rising antifungal drug resistance

In a recent study, researchers addressed the issue of the rise of antifungal drugs-resistant infections and the advent of multidrug-resistant fungal pathogens.

19 Jul 2023

AI and infection control: preventing infectious disease outbreaks and pandemics

Researchers discussed the role of artificial intelligence (AI) in preventing outbreaks of infectious diseases and future pandemics.

19 Jul 2023

Researchers find new genes that contribute to hypoplastic left heart syndrome

By identifying genes in patients and testing their effects in fruit flies, researchers from Sanford Burnham Prebys have found new genes that contribute to hypoplastic left heart syndrome (HLHS), a rare, life-threatening heart disease that occurs in infants.

17 Jul 2023

Griffith University researchers develop new method to control virus assembly

Griffith University researchers have played a key role in using DNA 'origami' templates to control the way viruses are assembled.

17 Jul 2023

PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board

PhoreMost Ltd. announced Professor Peter Parker and Dr Jason Imbriglio as members of its Scientific Advisory Board (SAB).

From PhoreMost 17 Jul 2023

Insilico Medicine and MIKADO team up to find new treatments for cystinosis

A team led by researchers at the Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (Zurich, Switzerland) has used Insilico Medicine's generative artificial intelligence (AI) target discovery engine, PandaOmics, to identify actionable drug targets for the lysosomal storage disease cystinosis and to validate them in preclinical models of the disease.

14 Jul 2023

AI-powered drug discovery offers hope for cystinosis patients

Artificial intelligence is becoming increasingly important in drug discovery. Advances in the use of Big Data, learning algorithms and powerful computers have now enabled researchers at the University of Zurich (UZH) to better understand a serious metabolic disease.